Hot Investor Mandate 2: Korean Pharma Seeks CNS, Infection, Oncology and Immunology Deals

21 Apr

A pharmaceutical company based in Korea is actively searching for innovative candidates and products around the world to incorporate into its pipeline and product portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is indication agnostic with added interest in CNS, infection, oncology, and immunology. The firm is also interested in other therapeutic areas that address unmet medical needs, including orphan diseases. The firm prefers assets from IND ready to late stage development. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; The firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: